Back to jobs
Job Description
Lycia Therapeutics is a biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop best-in-class therapeutics that degrade extracellular and membrane-bound proteins. These proteins drive a wide range of difficult-to-treat diseases, including autoimmune and inflammatory conditions. Lycia was established in 2019 in collaboration with academic founder and Nobel Laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University. In May 2024, Lycia Therapeutics completed a $106.6 million Series C financing to advance its pipeline of LYTAC extracellular protein degraders to the clinic. Lycia is headquartered in South San Francisco.
Position Summary
Lycia Therapeutics is seeking an experienced and highly resourceful Executive Assistant to provide senior-level support to our CEO, CFO, and General Counsel. This is a critical role for someone who thrives in a fast-moving, mission-driven biotech environment and excels at anticipating needs, managing competing priorities, and operating with a high degree of discretion. The ideal candidate brings polished executive support experience, exceptional judgment, and a proactive mindset that drives efficiency across the leadership team.
Position Summary
Lycia Therapeutics is seeking an experienced and highly resourceful Executive Assistant to provide senior-level support to our CEO, CFO, and General Counsel. This is a critical role for someone who thrives in a fast-moving, mission-driven biotech environment and excels at anticipating needs, managing competing priorities, and operating with a high degree of discretion. The ideal candidate brings polished executive support experience, exceptional judgment, and a proactive mindset that drives efficiency across the leadership team.
Lycia Therapeutics is a biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop best-in-class therapeutics that degrade extracellular and membrane-bound proteins. These proteins drive a wide range of difficult-to-treat diseases, including autoimmune and inflammatory conditions. Lycia was established in 2019 in collaboration with academic founder and Nobel Laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University. In May 2024, Lycia Therapeutics completed a $106.6 million Series C financing to advance its pipeline of LYTAC extracellular protein degraders to the clinic. Lycia is headquartered in South San Francisco.
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Lycia and other biotech companies have recently noticed an increase in email and social media scams targeting job candidates in our industry. Please note Lycia will post any legitimate job openings directly on our website or through our recruitment partner, Lever. If you wish to verify the legitimacy of a job opening, you may contact us.